LLY

1,049.29

+1.27%↑

JNJ

202.27

+1.25%↑

ABBV

231.12

-1.47%↓

UNH

308.13

-1.98%↓

AZN

88.73

-0.82%↓

LLY

1,049.29

+1.27%↑

JNJ

202.27

+1.25%↑

ABBV

231.12

-1.47%↓

UNH

308.13

-1.98%↓

AZN

88.73

-0.82%↓

LLY

1,049.29

+1.27%↑

JNJ

202.27

+1.25%↑

ABBV

231.12

-1.47%↓

UNH

308.13

-1.98%↓

AZN

88.73

-0.82%↓

LLY

1,049.29

+1.27%↑

JNJ

202.27

+1.25%↑

ABBV

231.12

-1.47%↓

UNH

308.13

-1.98%↓

AZN

88.73

-0.82%↓

LLY

1,049.29

+1.27%↑

JNJ

202.27

+1.25%↑

ABBV

231.12

-1.47%↓

UNH

308.13

-1.98%↓

AZN

88.73

-0.82%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.01 -0.98

Buy Sell

Overview

Share price change

24h

Current

Min

0.97

Max

1.04

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	5.5M -32M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+418.63% upside

Market Stats
By TradingEconomics
Market Cap	-13M 112M
Previous open	1.99
Previous close	1.01

News Sentiment

By Acuity

35%

65%

128 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 lis 2025, 19:25 UTC

Acquisitions, Mergers, Takeovers

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- 2nd Update

18 lis 2025, 18:09 UTC

Acquisitions, Mergers, Takeovers

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- Update

18 lis 2025, 17:39 UTC

Acquisitions, Mergers, Takeovers

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough

18 lis 2025, 16:25 UTC

Major Market Movers

Diginex Rises on Deal With Digital Asset Platform Evident

18 lis 2025, 23:56 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

18 lis 2025, 23:39 UTC

Market Talk

Nikkei May Rise on Bargain-Hunting Interest -- Market Talk

18 lis 2025, 22:59 UTC

Market Talk

FireFly Metals Can Build Bigger Operation at Green Bay -- Market Talk

18 lis 2025, 22:08 UTC

Market Talk

Sandfire's Kalkaroo Project Push Adds to Copper M&A Surge -- Market Talk

18 lis 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

Meta Defeats FTC's Antitrust Case Alleging Social-Media Monopoly -- 3rd Update

18 lis 2025, 22:03 UTC

Earnings

These Stocks Moved the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18 lis 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

18 lis 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18 lis 2025, 21:15 UTC

Market Talk

Private High-Grade Credit Market Is Changing, BlackRock Says -- Market Talk

18 lis 2025, 20:46 UTC

Market Talk

U.S. Natural Gas Futures Edge Up on Weather Outlook -- Market Talk

18 lis 2025, 20:13 UTC

Market Talk

Distillate Supply Concerns Pull Crude Futures Higher -- Market Talk

18 lis 2025, 19:48 UTC

Market Talk

Gold and Silver Turn Lower on Fed Outlook -- Market Talk

18 lis 2025, 19:19 UTC

Acquisitions, Mergers, Takeovers

Anheuser-Busch InBev Nears $700 Million Deal for Party Punch Maker BeatBox -- WSJ

18 lis 2025, 19:19 UTC

Acquisitions, Mergers, Takeovers

Anheuser-Busch InBev in Talks to Buy Party Punch Maker BeatBox, Sources Say -- WSJ

18 lis 2025, 19:19 UTC

Acquisitions, Mergers, Takeovers

AB InBev-BeatBox Deal Could Come Together Soon, Sources Say -- WSJ

18 lis 2025, 19:19 UTC

Acquisitions, Mergers, Takeovers

AB InBev Deal Would Value BeatBox At Around $700M, Sources Say -- WSJ

18 lis 2025, 18:29 UTC

Earnings

These Stocks Are Moving the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18 lis 2025, 18:18 UTC

Market Talk

Ethanol Demand Expected to Boost Corn Futures -- Market Talk

18 lis 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18 lis 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

18 lis 2025, 17:19 UTC

Market Talk

Earnings

Good Weather Was Bad News for Home Depot's 3Q -- Market Talk

18 lis 2025, 17:06 UTC

Earnings

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18 lis 2025, 16:06 UTC

Acquisitions, Mergers, Takeovers

Intuit Stock Gains on OpenAI Deal. ChatGPT Is Coming to TurboTax. -- Barrons.com

18 lis 2025, 15:59 UTC

Earnings

Home Depot Cuts Outlook as Home Improvement Slowdown Continues -- Update

18 lis 2025, 15:35 UTC

Acquisitions, Mergers, Takeovers

Eni: Acquisition Adds to Plenitude's Installed-Capacity Targets, Bolsters France Presence

18 lis 2025, 15:35 UTC

Acquisitions, Mergers, Takeovers

Eni: Portfolio Comprises Capacity of Around 760MW in Operation

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

418.63% upside

12 Months Forecast

Average 5.29 USD 418.63%

High 8 USD

Low 2 USD

Based on 9 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

128 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.